Abstract
HCV NS3, a serine protease, that when bound to NS-4A cofactor facilitates development of mature virons by catalyzing cleavage of a single polyprotein to form functional and structural proteins of HCV. X-ray structure of the enzyme reveal a very shallow binding pocket at the catalytic site which makes development of inhibitors a daunting task. Various novel approaches have been used to design, preorganized, depeptidized macrocyclic inhibitors linking the P2-P4 residues and P1-P3 groups. The design and structure activity relationship of these macrocyclic inhibitors are reviewed in the following article. X-ray structure of inhibitor bound to the active site of the enzyme is also discussed. Macrocyclization proved to be an effective tool for depeptidization of peptidic inhibitors, imparting enhanced metabolic stability and improved pharmacokinetic properties in the resultant molecules.
Keywords: Macrocyclization, HCV, NS3 protease, BILN-2061, depeptidization
Current Topics in Medicinal Chemistry
Title: Macrocyclic Inhibitors of HCV NS3-4A Protease: Design and Structure Activity Relationship
Volume: 7 Issue: 13
Author(s): Srikanth Venkatraman and F. George Njoroge
Affiliation:
Keywords: Macrocyclization, HCV, NS3 protease, BILN-2061, depeptidization
Abstract: HCV NS3, a serine protease, that when bound to NS-4A cofactor facilitates development of mature virons by catalyzing cleavage of a single polyprotein to form functional and structural proteins of HCV. X-ray structure of the enzyme reveal a very shallow binding pocket at the catalytic site which makes development of inhibitors a daunting task. Various novel approaches have been used to design, preorganized, depeptidized macrocyclic inhibitors linking the P2-P4 residues and P1-P3 groups. The design and structure activity relationship of these macrocyclic inhibitors are reviewed in the following article. X-ray structure of inhibitor bound to the active site of the enzyme is also discussed. Macrocyclization proved to be an effective tool for depeptidization of peptidic inhibitors, imparting enhanced metabolic stability and improved pharmacokinetic properties in the resultant molecules.
Export Options
About this article
Cite this article as:
Srikanth Venkatraman and F. George Njoroge , Macrocyclic Inhibitors of HCV NS3-4A Protease: Design and Structure Activity Relationship, Current Topics in Medicinal Chemistry 2007; 7 (13) . https://dx.doi.org/10.2174/156802607781212202
DOI https://dx.doi.org/10.2174/156802607781212202 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Inhibitors of Cytosolic Phospholipase A2α as Potential Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review
Current Medicinal Chemistry Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Protease Inhibitors in the Clinic
Medicinal Chemistry The Influence of Ionizing Radiation on Exosome Composition, Secretion and Intercellular Communication
Protein & Peptide Letters Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Donkeys and Goats Milk Consumption and Benefits to Human Health with Special Reference to the Inflammatory Status
Current Pharmaceutical Design Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role?
Current Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry